» Articles » PMID: 15095038

Glucagon-like Peptide-1 Prevents Beta Cell Glucolipotoxicity

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2004 Apr 20
PMID 15095038
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: We have provided evidence that glucagon-like peptide-1, a potential therapeutic agent in the treatment of diabetes, activates phosphatidylinositol-3 kinase/protein kinase B signalling in the pancreatic beta cell. Since this pathway promotes cell survival in a variety of systems, we tested whether glucagon-like peptide-1 protects beta cells against cell death induced by elevated glucose and/or non-esterified fatty acids.

Methods: Human islets and INS832/13 cells were cultured at glucose concentrations of 5 or 25 mmol/l in the presence or absence of palmitate. Apoptosis was evaluated by monitoring DNA fragmentation and chromatin condensation. Wild-type and protein kinase B mutants were overexpressed in INS832/13 cells using adenoviruses. Nuclear factor-kappa B DNA binding was assayed by electrophoretic mobility shift assay.

Results: In human pancreatic beta cells and INS832/13 cells, glucagon-like peptide-1 prevented beta cell apoptosis induced by elevated concentrations of (i) glucose (glucotoxicity), (ii) palmitate (lipotoxicity) and (iii) both glucose and palmitate (glucolipotoxicity). Overexpression of a dominant-negative protein kinase B suppressed the anti-apoptotic action of glucagon-like peptide-1 in INS832/13 cells, whereas a constitutively active protein kinase B prevented beta cell apoptosis induced by elevated glucose and palmitate. Glucagon-like peptide-1 enhanced nuclear factor-kappa B DNA binding activity and stimulated the expression of inhibitor of apoptosis protein-2 and Bcl-2, two anti-apoptotic genes under the control of nuclear factor-kappa B. Inhibition of nuclear factor-kappa B by BAY 11-7082 abolished the prevention of glucolipotoxicity by glucagon-like peptide-1.

Conclusions/interpretation: The results demonstrate a potent protective effect of glucagon-like peptide-1 on beta cell gluco-, lipo- and glucolipotoxicity. This effect is mediated via protein kinase B activation and possibly its downstream target nuclear factor-kappa B.

Citing Articles

Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.

Gojani E, Wang B, Li D, Kovalchuk O, Kovalchuk I Int J Mol Sci. 2025; 26(1.

PMID: 39796271 PMC: 11720205. DOI: 10.3390/ijms26010421.


Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.

Merzeban D, El Amin Ali A, Hammad R, Elmahdi M, Sofi M, Mahmoud R J Mol Histol. 2024; 56(1):50.

PMID: 39704859 DOI: 10.1007/s10735-024-10326-x.


GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.

Holst J Nat Metab. 2024; 6(10):1866-1885.

PMID: 39160334 DOI: 10.1038/s42255-024-01113-9.


Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.

Heckmann N, Palmer R, Mayfield C, Gucev G, Lieberman J, Hong K Arthroplast Today. 2024; 27:101327.

PMID: 39071832 PMC: 11282421. DOI: 10.1016/j.artd.2024.101327.


A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium among Various Organ Systems.

Barakat G, Assi G, Khalil H, Khatib S Curr Diabetes Rev. 2024; 21(2):e160424228945.

PMID: 38629376 DOI: 10.2174/0115733998287178240403055901.


References
1.
Diaz-Meco M, Berra E, Municio M, Sanz L, Lozano J, Dominguez I . A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol. 1993; 13(8):4770-5. PMC: 360103. DOI: 10.1128/mcb.13.8.4770-4775.1993. View

2.
Mattson M, Camandola S . NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001; 107(3):247-54. PMC: 199201. DOI: 10.1172/JCI11916. View

3.
Thorens B . Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992; 89(18):8641-5. PMC: 49976. DOI: 10.1073/pnas.89.18.8641. View

4.
Roduit R, Morin J, Masse F, Segall L, Roche E, Newgard C . Glucose down-regulates the expression of the peroxisome proliferator-activated receptor-alpha gene in the pancreatic beta -cell. J Biol Chem. 2000; 275(46):35799-806. DOI: 10.1074/jbc.M006001200. View

5.
Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Ju S . Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J Immunol. 1998; 161(7):3469-73. View